Aminolevulinic acid - DUSA

Drug Profile

Aminolevulinic acid - DUSA

Alternative Names: 5 ALA; 5-Aminolaevulinic acid; 5-Aminolevulinic acid; ALA - DUSA; aminolevulinic acid HCL - DUSA; Delta-aminolevulinic acid; Levulan PDT; Levulan photodynamic therapy; Levulan/Kerastick; Levulan™

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PARTEQ Innovations
  • Developer Cleveland Clinic; DUSA Pharmaceuticals
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal dysplasia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Basal cell nevus syndrome; Brain cancer
  • Suspended Warts
  • No development reported Barrett's oesophagus
  • Discontinued Acne vulgaris; Leucoplakia; Oesophageal cancer; Photodamage; Psoriasis; Skin cancer

Most Recent Events

  • 03 Nov 2017 DUSA Pharmaceuticals withdraws a phase III trial for Actinic keratosis prior to enrolment in USA due to corporate business decision (Topical) (NCT03024060)
  • 24 Jan 2017 DUSA Pharmaceuticals plans a phase III trial for Actinic keratosis in USA (Topical) (NCT03024060)
  • 12 Sep 2016 DUSA Pharmaceuticals completes a phase II trial in Actinic keratosis in USA (Topical) (NCT02632110)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top